1. |
- Hukkanen, J., et al.
(författare)
-
The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity
- 2015
-
Ingår i: British Journal of Clinical Pharmacology. - : Blackwell Publishing. - 0306-5251 .- 1365-2125. ; 80:3, s. 473-479
-
Tidskriftsartikel (refereegranskat)abstract
- Aims: Atorvastatin is known to both inhibit and induce the cytochrome P450 3A4 (CYP3A4) enzyme in vitro. Some clinical studies indicate that atorvastatin inhibits CYP3A4 but there are no well-controlled longer term studies that could evaluate the inducing effect of atorvastatin. We aimed to determine if atorvastatin induces or inhibits CYP3A4 activity as measured by the 4β-hydroxycholesterol to cholesterol ratio (4βHC : C).Methods: In this randomized, double-blind, placebo-controlled 6 month study we evaluated the effects of atorvastatin 20mg day1 (n=15) and placebo (n = 14) on oxysterol concentrations and determined if atorvastatin induces or inhibits CYP3A4 activity as assessed by the 4βHC : C index. The respective 25-hydroxycholesterol and 5α,6α- epoxycholesterol ratios were used as negative controls.Results: Treatment with atorvastatin decreased 4βHC and 5α,6α-epoxycholesterol concentrations by 40% and 23%, respectively. The mean 4βHC : C ratio decreased by 13% (0.214 ± 0.04 to 0.182 ± 0.04, P = 0.024, 95% confidence interval (CI) of the difference –0.0595, –0.00483) in the atorvastatin group while no significant change occurred in the placebo group. The difference in change of 4βHC : C between study arms was statistically significant (atorvastatin –0.032, placebo 0.0055, P = 0.020, 95% CI of the difference – 0.069, –0.0067). The ratios of 25-hydroxycholesterol and 5α,6α- epoxycholesterol to cholesterol did not change.Conclusions: The results establish atorvastatin as an inhibitor of CYP3A4 activity.Furthermore, 4βHC : C is a useful index of CYP3A4 activity, including theconditions with altered cholesterol concentrations.
|
|
2. |
|
|
3. |
|
|
4. |
- Bastani, H, et al.
(författare)
-
Cryothermal vs. radiofrequency ablation as atrial flutter therapy: a randomized comparison
- 2013
-
Ingår i: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. - : Oxford University Press (OUP). - 1532-2092. ; 15:3, s. 420-428
-
Tidskriftsartikel (refereegranskat)
|
|
5. |
|
|
6. |
|
|
7. |
|
|
8. |
|
|
9. |
- Jemtren, A, et al.
(författare)
-
Risk assessment in patients with symptomatic and asymptomatic pre-excitation
- 2024
-
Ingår i: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. - 1532-2092. ; 26:2
-
Tidskriftsartikel (refereegranskat)
|
|
10. |
|
|